A severe traumatic brain injury can make it hard to remember recent events or conversations. But a form of brain stimulation appears to ease this memory deficit.
It can be heartbreaking to let go of a hand-made rug or sweater that a loved one didn't quite finish. A group of volunteer knitters, quilters and other crafters offer some closure.
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.
The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.
Diseases like Alzheimer's and Parkinson's spread through the brain like a forest fire. A new study suggests how the fire starts.
Friday on Political Rewind: In this pre-recorded conversation we discuss the outpouring of support for former first lady Rosalynn Carter as her family announced her dementia diagnosis. This news comes as she spent decades fighting to erase mental health stigma and find support for caregivers. We talk to executives at the Carter Center and the Rosalynn Carter Institute for Caregivers about her legacy.
Scientists have shown that deep brain stimulation during sleep can help people retain new information. The approach could help people with memory problems related to disorders like Alzheimer's.
Reckless behavior with money can be a warning sign of cognitive decline — and the condition can put people at risk of financial ruin. There are few institutional safeguards in place.
The woman was unresponsive, and nurses were unable to detect her breathing. A state agency report found the facility "failed to ensure residents received dignified treatment and care at end of life."
Photographer Lori Grinker struggled to get along with her mother all of her life. When she moved in with her to help with her failing health, old wounds melted away.
In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.
For some people, a rare genetic mutation makes dementia inescapable. Three sisters have decided to confront fate with a genetic test and have joined a research project on possible treatments.
This week’s Medical Minute, discusses seizures experienced by Alzheimer’s patients and a novel peptide, which can be delivered via a nasal spray, that can tamp down this abnormal electrical activity and reduce resulting damage to brain cells.